Det skal alvorligt overvejes at afbryde behandlingen med Herceptin hos patienter, som får klinisk signifikant hjerteinsufficiens, medmindre fordelen for den enkelte patient synes at opveje risikoen.
Discontinuation of Herceptin therapy should be strongly considered in patients who develop clinically significant heart failure unless the benefits for an individual patient are deemed to outweigh the risks.